Retour sur lavenir.net
   UCB 210.300 € (-0,14 %)     NYXOAH 1.426 € (-4,68 %)     WDP 21.260 € (-1,76 %)     KINEPOLIS GROUP 48.150 € (-0,82 %)     ELIA GROUP 120.400 € (+1,09 %)     CENERGY 23.620 € (+2,87 %)     ASCENCIO 53.300 € (0,00 %)     DEME GROUP 181.400 € (-0,87 %)     AGEAS 75.750 € (-0,85 %)     JENSEN-GROUP 75.600 € (0,00 %)     XIOR 26.100 € (-3,51 %)     AGFA-GEVAERT 0.411 € (-2,38 %)     KBC ANCORA 95.700 € (+0,53 %)     ENERGYVISION 16.920 € (-1,63 %)     EVS 28.900 € (-1,03 %)     TUBIZE-FIN 177.900 € (-0,45 %)     CMB.TECH 16.800 € (+0,12 %)     DECEUNINCK 2.385 € (0,00 %)     RECTICEL 12.480 € (-3,26 %)     VAN DE VELDE 30.000 € (0,00 %)     AEDIFICA 67.150 € (-0,44 %)     BELYSSE GROUP 0.422 € (-7,05 %)     HOME INVEST BE. 18.680 € (-1,89 %)     TITAN S.A. 53.300 € (-1,57 %)     COLRUYT 39.380 € (-0,35 %)     SOFINA 255.600 € (+1,43 %)     D'IETEREN GROUP 176.400 € (-2,22 %)     INCLUSIO SA/NV 16.900 € (+0,60 %)     CIE BOIS SAUVAGE 308.000 € (0,00 %)     SHURGARD 22.350 € (-2,61 %)     SYENSQO 80.350 € (-1,23 %)     FAGRON 21.700 € (+0,23 %)     BEKAERT 38.850 € (-1,40 %)     GIMV 45.600 € (+1,79 %)     RETAIL ESTATES 65.400 € (-1,65 %)     ATENOR 1.150 € (-4,17 %)     AB INBEV 68.020 € (-1,48 %)     ARGENX SE 869.400 € (-2,71 %)     MONTEA 64.700 € (-0,92 %)     SIPEF 105.200 € (+0,96 %)     AZELIS GROUP 12.000 € (-2,52 %)     TINC 11.180 € (-0,53 %)     UMICORE 22.620 € (-1,31 %)     FLUXYS BELGIUM D 22.300 € (-2,19 %)     BARCO 7.995 € (-0,62 %)     PROXIMUS 6.260 € (-1,34 %)     CAMPINE 182.000 € (-1,09 %)     BPOST 1.280 € (-1,08 %)     CARE PROPERTY INV. 12.440 € (-1,43 %)     KBC 134.400 € (+0,90 %)     HYLORIS 4.400 € (-2,00 %)     IMMOBEL 21.000 € (+3,45 %)     NEXTENSA 46.200 € (-1,35 %)     MELEXIS 67.850 € (+3,04 %)     SOLVAC NOM(RETAIL) 85.000 € (+0,59 %)     VASTNED 28.500 € (-1,04 %)     ONTEX GROUP 2.340 € (-4,49 %)     ONWARD MEDICAL 2.500 € (-0,20 %)     WERELDHAVE BELGIUM 51.000 € (+0,79 %)     ORANGE BELGIUM 22.100 € (0,00 %)  
   LISI 61.000 € (+0,33 %)     VALLOUREC 18.865 € (+1,21 %)     MAAT PHARMA 2.880 € (-2,04 %)     TOTALENERGIES 77.300 € (+1,58 %)     WORLDLINE 14.212 € (-2,31 %)     GTT 220.000 € (+1,76 %)     EUROPLASMA 0.001 € (+33,33 %)     ASR NEDERLAND 73.960 € (-0,62 %)     SHOWROOMPRIVE 1.050 € (+9,38 %)     SHELL PLC 40.560 € (+1,13 %)     ARKEMA 59.050 € (-0,42 %)     SARTORIUS STED BIO 186.500 € (-2,00 %)     MERSEN 38.700 € (+2,54 %)     ALSTOM 16.300 € (-1,21 %)     SAINT GOBAIN 74.620 € (-1,53 %)     VINCI 113.600 € (-0,31 %)     EXOSENS 57.450 € (+4,08 %)     MICHELIN 34.470 € (-1,96 %)     BENETEAU 5.690 € (-1,39 %)     SOLUTIONS 30 SE 0.538 € (-0,55 %)     CROSSJECT 1.400 € (+4,48 %)     ADP 108.200 € (-1,10 %)     RIBER 9.480 € (+10,75 %)     ARCADIS 43.980 € (-0,99 %)     ROBERTET 791.000 € (-0,75 %)     CARREFOUR 16.270 € (-0,82 %)     BNP PARIBAS ACT.A 104.540 € (0,00 %)     TETRAGON FIN GRP 14.100 € (+0,71 %)     CRCAM BRIE PIC2CCI 37.200 € (+0,54 %)     AMG 32.660 € (+3,55 %)     KERING 241.400 € (-1,55 %)     CASINO GUICHARD 0.184 € (-0,16 %)     ESSILORLUXOTTICA 148.550 € (-0,83 %)     ACCOR 46.650 € (-0,53 %)     IMERYS 24.660 € (+1,40 %)     PHARMING GROUP 0.982 € (+1,34 %)     ATOS GROUP 26.220 € (-2,24 %)     HAFFNER ENERGY 0.668 € (+12,84 %)     SCHNEIDER ELECTRIC 295.500 € (+2,60 %)     AKZO NOBEL 60.160 € (-0,95 %)     VICAT 65.700 € (+0,31 %)     AHOLD DEL 31.100 € (-1,77 %)     PARROT 9.250 € (-1,28 %)     SPIE 43.780 € (-0,05 %)     ABN AMRO BANK N.V. 43.420 € (+0,67 %)     WINFARM 3.900 € (0,00 %)     WAVESTONE 31.800 € (-1,24 %)     SOITEC 143.350 € (+11,73 %)     ARCELORMITTAL SA 67.540 € (+0,45 %)     SOCIETE GENERALE 75.070 € (+1,20 %)     ALTAREA 88.700 € (-2,53 %)     KAUFMAN ET BROAD 22.550 € (-2,38 %)     ARGAN 72.400 € (-1,76 %)     SANOFI 75.690 € (-0,75 %)     CREDIT AGRICOLE 18.865 € (+0,32 %)     CTP 13.700 € (-1,30 %)     AMOEBA 0.629 € (+0,64 %)     OMER-DECUGIS & CIE 8.400 € (0,00 %)     ASM INTERNATIONAL 862.200 € (+4,48 %)     AXA 44.160 € (-1,08 %)  
News Réglementées
07/09/2026 09:31

Synnovis and Apian partner to advance drone and autonomous robotics in healthcare logistics

EQS-News: SYNLAB / Key word(s): Miscellaneous
Synnovis and Apian partner to advance drone and autonomous robotics in healthcare logistics

07.09.2026 / 09:31 CET/CEST
The issuer is solely responsible for the content of this announcement.


The latest milestone for the teams behind the UK’s first medical drone delivery service

SYNLAB Group is pleased to announce Synnovis* and Apian’s strategic partnership to further develop the use of drones and autonomous robotics in pathology logistics. This collaboration will improve the speed, resilience and cost effectiveness of sample delivery to better support our customers and partners.

This follows a successful pilot which began in 2024, delivering over 6,000 pathology samples between the Synnovis labs at Guy’s and St Thomas’ hospitals, in south east London. The drone deliveries are zero emission during flight, and samples were transported between sites in less than two minutes compared to more than half an hour by road.

This autumn, Synnovis will expand its use of drone logistics with Apian deploying Matternet drones to transport urgent samples in London, from both Guy’s Hospital and St Thomas’ Hospital for specialist testing at the Synnovis Blackfriars laboratory hub.

The first of these flights will carry bone marrow samples critical for the diagnosis and monitoring of blood disorders such as acute leukaemia, including for paediatric patients treated at Evelina London Children’s Hospital. The enhanced speed of sample delivery will allow scientists across Synnovis, one of SYNLAB UK & Ireland’s four NHS partnerships, to provide results more quickly and support well-informed patient care.

This expanded drone delivery service includes new use cases and represents a significant milestone in autonomous logistics, with plans for routes to serve additional Synnovis customers underway.

Professor Dominic Harrington, Chief Scientific Officer, SYNLAB UK & Ireland, said:

“Our scientists perform cutting-edge medical diagnostics every day. Working with Apian to implement drone delivery allows us to extend innovation beyond the lab and into the entire sample pathway.”

“Our Blackfriars hub analyses 20,000 samples each day, and each one of those samples represents a patient. Efficient logistics are key to enabling us to provide a successful service for every patient we serve. Extending our drone network will help us ensure we get the right samples, to the right place, at the right time to support clinicians and their patients when they need it most. This partnership with Apian puts us at the forefront of pathology logistics.”

Mark Dollar, CEO, SYNLAB UK & Ireland said:

“This partnership builds on several years of collaboration with Apian, including on this pioneering medical drone project, and marks an important milestone. It represents a strategic investment which will allow us to explore innovation opportunities in robotics, AI and autonomous logistics across both Synnovis and the wider SYNLAB Group.”

Alexander Trewby, Co-Founder and CEO of Apian, said:

“Healthcare will ultimately be enabled by fleets of autonomous systems. Our role is to provide the orchestration layer that connects those systems with clinical operations. We’re delighted to have extended our collaboration with Synnovis, Apian’s first pathology partner in the UK, and to further advance the use of autonomous logistics into laboratory medicine. We’re looking forward to exploring an exciting future together.”

– Ends –

Notes

*Synnovis is a partnership between SYNLAB UK & Ireland, Guy’s and St Thomas’ NHS Foundation Trust and Kings College Hospital NHS Foundation Trust.

 

For more information:

 

Media Contact
Daniel Herbert, FTI Consulting 
+ 49 (0) 151 12263834 
media-contact@synlab.com

 

About SYNLAB

  • SYNLAB Group is a leader in medical diagnostic services and specialty testing in Europe. The Group offers a full range of innovative and reliable medical diagnostics to patients, practising doctors, hospitals and clinics, governments and corporations.
  • Providing the leading level of service within the industry, SYNLAB is the partner of choice for routine and specialty diagnostics in human medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
  • SYNLAB operates in more than 20 countries across four continents and holds leading positions in most markets, regularly reinforcing the strength of its network through a proven acquisition strategy. More than 23,000 employees, including over 2,000 medical experts, contribute every day to the Group’s worldwide success.
  • SYNLAB performed around 600 million laboratory tests and achieved revenues of €2.54 billion in 2025.
  • More information can be found on www.synlab.com


07.09.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2394876  07.09.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière